特发性肺纤维化疫苗接种后急性加重病例报告
本文报告首例特发性肺纤维化患者在接种SARS-CoV-2疫苗后出现急性加重的病例,提示疫苗接种可能触发急性加重。间质性肺病急性加重与疫苗的关联尚未明确,目前关于疫苗对肺部不良反应的数据很少。
要点
- 首例报告SARS-CoV-2疫苗接种可能触发特发性肺纤维化急性加重。
- 间质性肺病急性加重与疫苗的关联尚未明确。
- 疫苗对肺部不良反应的数据很少。
核心结论
- 本病例报告提示SARS-CoV-2疫苗接种可能触发特发性肺纤维化急性加重,但关联尚未明确。
研究设计与样本
- 病例报告(首例报告),具体样本量原文未报告。
主要发现
- 描述了首例特发性肺纤维化患者接种SARS-CoV-2疫苗后发生急性加重的病例。
临床怎么用
- 呼吸科医生在特发性肺纤维化患者接种SARS-CoV-2疫苗后应关注急性加重的可能。
局限性
- 仅为个案报告,无法确立因果关系;疫苗对肺部不良反应的数据很少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although the association between acute exacerbation of interstitial lung disease and vaccination is not yet clarified, this is the first case report describing the possibility that SARS-CoV-2 vaccination may trigger acute exacerbation https://bit.ly/3tpu6Cz Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has spread worldwide and coronavirus disease 2019 remains a major health concern. Several SARS-CoV-2 vaccines have been produced and are playing important roles in the prevention of infection and worsening to a severe state, and in improving mortality [1]. However, some concerns about adverse effects related to SARS-CoV-2 vaccination have been raised. Recently, various adverse effects have been reported, but there is little data on adverse effects on the lungs [2].
引用
- Bando T, Takei R, Mutoh Y, et al. Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination. Eur Respir J. 2022. PMID: 35144990. doi:10.1183/13993003.02806-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。